Tolstrup
Anne B. Tolstrup, Hillerod DK
Patent application number | Description | Published |
---|---|---|
20090137003 | Methods for recombinant manufacturing of anti-RSV antibodies - The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses. | 05-28-2009 |
20120009623 | Methods for Recombinant Manufacturing of Anti-RSV Antibodies - The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses. | 01-12-2012 |
Anne Bondgaard Tolstrup, Hillroed DK
Patent application number | Description | Published |
---|---|---|
20090111142 | Method for manufacturing a recombinant polyclonal protein - The invention relates to a method for manufacturing a recombinant polyclonal protein composition, in particular a recombinant polyclonal antibody composition. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one member of the collection, which encodes a distinct member of a polyclonal protein. The cells are cultured under suitable conditions for expression of the polyclonal protein, which is obtained from the cells or culture supernatant. The nucleic acid sequence is introduced into the cells by transfection with a collection of vectors. The present method is suitable for manufacturing recombinant polyclonal antibodies for therapeutic uses. | 04-30-2009 |
Anne Bondgaard Tolstrup, Hillerod DK
Patent application number | Description | Published |
---|---|---|
20090017017 | Anti-rhesus d recombinant polyclonal antibody and methods of manufacture - The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immonoglobulin products. | 01-15-2009 |
20120322690 | Anti-Rhesus D Recombinant Polyclonal Antibody and Methods of Manufacture - The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. Nucleic acid segments encoding the anti-RhD rpAb are introduced into the cells by transfection with a library of vectors for site-specific integration. The method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immunoglobulin products. | 12-20-2012 |
Anne Bondgaard Tolstrup, Hilleroed DK
Patent application number | Description | Published |
---|---|---|
20110117605 | Methods for Manufacturing a Polyclonal Protein - The invention relates to methods for manufacturing drug products comprising at least two distinct members of a polyclonal protein, for example a polyclonal antibody, where each distinct member is expressed by a separate population of cells. The methods involve at least an initial step in which the cell populations expressing the distinct members of the polyclonal protein are cultured separately. The individual cell populations, or proteins expressed by the individual cell populations, are combined at a later point of the upstream or downstream processing to result in a single drug product comprising the distinct members of the polyclonal protein. | 05-19-2011 |
Martin Tolstrup, Risskov DK
Patent application number | Description | Published |
---|---|---|
20110305749 | HIV-1 Envelope Polypeptides for HIV Vaccine - Immunogenic HIV-1 envelope polypeptides are provided, wherein specific amino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic properties of the viral particle and/or the overall protein structure of the viral envelope protein. The invention further provides peptides and antigens based on the immunogenic HIV-1 envelopes as well as nucleic acid sequences and vectors encoding those. Moreover, biological entities such as viral particles are provided, as well as use of the provided components for preparation of a vaccine against HIV-1/AIDS. | 12-15-2011 |
20130108653 | BIVALENT MOLECULES FOR HIV ENTRY INHIBITION | 05-02-2013 |
20150031739 | PANOBINOSTAT FOR USE IN THE TREATMENT OF HIV-1 - The present invention relates to uses and methods involving Panobinostat and HIV-1. In particular relates the present invention to Panobinostat for use in the treatment of HIV-1 and especially latent HIV-1. This is done using a low dosage of Panobinostat which is highly effective in depleting the HIV-1 reservoir. | 01-29-2015 |
Martin Tolstrup, Aarhus N DK
Patent application number | Description | Published |
---|---|---|
20090324553 | Chimeric Viral Envelopes - The invention relates to chimeric polytropic viral envelope polypeptides and uses thereof, as well as to polynucleotides encoding said chimeric polypeptides and constructs comprising said polypeptides and/or polynucleotides. The invention also relates to chimeric retroviral envelope polypeptides, polynucleotides and vectors encoding said chimeric retroviral envelope polypeptides, virus particles and cells harbouring said chimeric envelope polypeptides. Said chimeric polypeptide comprise an envelope polypeptide, or fragment thereof, and a polypeptide sequence of a receptor binding region, ligand or polypeptide sequence of a ligand binding region, and optionally a linker sequence. The invention include methods of targeting receptors, methods of treatment and methods for delivery of agents using said chimeric retroviral envelope polypeptides. The invention is applicable for directed targeting and controlled fusion of virus particles with other cellular membranes. | 12-31-2009 |
Morten Tolstrup, Dronninglund DK
Patent application number | Description | Published |
---|---|---|
20100202356 | BACKFIRE DISTRIBUTED ANTENNA SYSTEM (DAS) WITH DELAYED TRANSPORT - A distributed antenna system (DAS) is provided, comprising a host unit and a plurality of remote placed to define a common coverage area. Each of the plurality of remote units is communicatively coupled to the host unit, points at least partially towards the common coverage area, and simulcasts data from the host unit. | 08-12-2010 |
Niels Tolstrup, Klampenborg DK
Patent application number | Description | Published |
---|---|---|
20120157333 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST - The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample. | 06-21-2012 |